Nirav Niranjan Shah, MD, MS Medical College of Wisconsin 5Live #ASCO20
4:51
Key Insights on Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.
Key Insights on Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.
Diffuse Large B Cell Lymphoma Similar Videos
-
Recent Advances in the Frontline Treatment of DLBCL: Is There a New Standard of Care?_Laurie Sehn, MD, MPH; #IUCLS22
49:11
-
Module 4_Integrating Novel Approaches in Clinical Practice & Key Takeaways_Gilles Salles, MD, PhD_Christopher Flowers, MD, MS_Laurie Sehn, MD, MPH
19:16
-
Prevention of CNS Progression in Diffuse Large B-cell Lymphoma_Craig Portell, MD; #IUCLS22
19:43